RECORDATORIO: Nuestro equipo de la línea de atención telefónica está trabajando a distancia y centrando su tiempo en ayudar a nuestros pacientes. Agradecemos a las farmacias, a los proveedores y a su personal que utilicen nuestros Portales de Farmacia y de Proveedores. Por favor, tenga en cuenta que si se pone en contacto con nosotros sobre un pago o una subvención, es más rápido enviarnos un correo electrónico a [email protected]. Le agradecemos su paciencia y esperamos seguir sirviéndole. Les deseamos a todos seguridad y buena salud durante estos momentos difíciles. El equipo de HealthWell
Non-Small Cell Lung Cancer - Medicare Access (Medicare patients only)
Status
ClosedThis fund is temporarily closed to new patients due to lack of sufficient funding. Please continue to visit our Disease Funds page often, as replenished funds reopen as quickly as possible. If you currently have a grant with HealthWell, your grant will remain active for the entire 12 month grant cycle or until you have exhausted your allocated grant amount, whichever comes first. You can continue to use your pharmacy card or submit requests for reimbursements during your designated grant cycle.
Fund Type
CopayPremium (Medicare Part B only)
Maximum Award Level
Pharmacy Card Fund
YesMinimum CopayReimbursement Amount
We encourage you to please use your HealthWell pharmacy card for any applicable charges as possible.
Minimum Premium
Reimbursement Amount
Household Income Limit
400% of the Federal Poverty Level(adjusted for household size and high
cost of living areas)
Treatments Covered
- Abraxane
- Afatinib Dimaleate
- Alecensa
- Alimta
- Alunbrig
- Atezolizumab
- Augtyro
- Avastin
- Bevacizumab
- Bevacizumab-awwb
- Brigatinib
- Cabometyx
- Camptosar
- Carboplatin
- Ceenu
- Ceritinib
- Cetuximab
- Cisplatin
- Cometriq
- Crizotinib
- Cyramza
- Docetaxel
- Doxorubicin Hydrochloride
- Durvalumab
- Ellence
- Enhertu
- Entrectinib
- Epirubicin
- Erbitux
- Erlotinib
- Erlotinib Hydrochloride
- Etopophos
- Etoposide
- Exkivity
- Gavreto
- Gemcitabine Hydrochloride
- Gemzar
- Gilotrif
- Gleostine
- Herceptin
- Herzuma
- Hycamtin
- Ifex
- Imfinzi
- Iressa
- Irinotecan
- Kanjinti
- Keytruda
- Krazati
- Libtayo
- Lomustine
- Lorbrena
- Lorlatinib
- Lumakras
- Mechlorethamine Hydrochloride
- Mekinist
- Mesnex
- Methotrexate
- Methotrexate Lpf
- Mustargen
- Mvasi
- Navelbine
- Nexavar
- Nivolumab
- Ontruzant
- Opdivo
- Paclitaxel
- Paraplatin
- Pemetrexed
- Pemrydi Rtu
- Photofrin
- Platinol
- Platinol-aq
- Portrazza
- Ramucirumab
- Retevmo
- Rozlytrek
- Rybrevant
- Sutent
- Tabrecta
- Tafinlar
- Tagrisso
- Tarceva
- Taxol
- Taxotere
- Tecentriq
- Tecentriq Hebreza
- Tepmetko
- Thalomid
- Trastuzumab-qyyp
- Trazimera
- Vinblastine Sulfate
- Vinorelbine Tartrate
- Vizimpro
- Xalkori
- Xgeva
- Yervoy
- Zelboraf
- Zirabev
- Zoledronic Acid
- Zometa
- Zykadia
Fund Definition
Assistance with the prescription drugs and biologics used in the treatment of non-small cell lung cancer.
Grant Utilization
HealthWell estimates that patients use an average of $3,860 during their 12-month grant period for this disease area.
Do I Qualify?
HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:
-
Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Disease Funds listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.
-
This is a Medicare Access Fund. In order to qualify for premium assistance through this fund, you must have Medicare Part B. The Foundation will refer patients without Medicare to other programs, such as manufacturer patient assistance programs.
-
HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.
-
If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.
About Non-Small Cell Lung Cancer
Lung cancer forms in tissues of the lung, usually in the cells lining air passages. The two main types are small cell lung cancer and non-small cell lung cancer. These types are diagnosed based on how the cells look under a microscope. NSCLC typically grows and spreads more slowly than small cell lung cancer. Some lung cancer tumors are composed of cells from more than one type of NSCLC. Source: National Cancer Institute, Lung Cancer Alliance
Additional Educational Resources
- American Cancer Society
- CancerCare
- LiveLung
- Lung Cancer Alliance
- LUNGevity Foundation
- National Cancer Institute
You may also visit our Resource List to view other copayment organizations that may provide assistance.